Boston Scientific Announces U.S. and European Launch of Interlock - 35 Fibered IDC Occlusion System

Boston Scientific Corporation BSX today announced the immediate U.S. and European launch of its Interlock™ – 35 Fibered IDC™ Occlusion System. Earlier this year, the system received clearance from the U.S. Food and Drug Administration and CE Mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures. The Interlock – 35 System consists of a 0.035" detachable coil that features a unique interlocking connection between the coil and delivery wire designed to offer excellent placement control, including the ability to advance, retract and reposition the coil before final deployment in the vessel. The coil is engineered to be accurately and reliably detached by simply pushing the detachment zone beyond the distal end of the 5F delivery catheter. The platinum coil is constructed with a dense network of synthetic fibers, designed to offer excellent thrombogenicity (blockage of blood flow) and rapid stasis. "Compatibility with 5F catheters allows for placement of larger coils, which can help achieve peripheral embolization with fewer coils, potentially reducing procedure times," said Sally Mitchell, M.D., Professor of Radiology, Surgery and Pediatrics at The Johns Hopkins University School of Medicine in Baltimore, MD. "The Interlock – 35 Coil provides excellent occlusive power while allowing precise retrievable placement, representing a major advantage over standard 0.035" pushable coil technology."